Associate Professor Vanderbilt University Medical Center
Identify appropriate use of genetic testing and genetic counseling.
Identify appropriate use of somatic testing and treatments related to specific genetic alterations.
Identify appropriate combination therapy with ADT plus novel androgen access therapies and chemotherapy.
Discuss the treatments for non-metastatic CRPC and their urologic outcomes.
Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing.
This course will be comprehensive in the approach to the diagnosis, management and outcomes of men with advanced, metastatic and castrate-resistant prostate cancer (CRPC). The course will include germline testing, positron emission tomography (PET) imaging, the use of combination androgen deprivation therapy (ADT) in combination with novel androgen axis therapy, and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). The course will also cover non-metastatic CRPC, and treatment for metastatic CRPC. The use of sequencing, combination therapy, somatic testing and precision medicine with PARP inhibitors will also be discussed. The course will also cover emerging salvage therapies for CRPC.